MRSN — Mersana Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $49.31m
- -$10.31m
- $40.50m
Annual income statement for Mersana Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.828 | 0.043 | 26.6 | 36.9 | 40.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 88.9 | 169 | 230 | 217 | 114 |
| Operating Profit | -88.1 | -169 | -204 | -180 | -73.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -88 | -170 | -204 | -172 | -68.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -88 | -170 | -204 | -172 | -69.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -88 | -170 | -204 | -172 | -69.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -88 | -170 | -204 | -172 | -69.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -35.8 | -60.2 | -54.5 | -35.1 | -14.1 |